ABOUT

Based on innovative scientific achievements,
Pimedbio's first-in-class drugs
  • home
  • About
  • Startup Story

Startup Story

Startup Story

We create new treatments based on cutting-edge approaches.

Our company was founded in response to the groundbreaking advancements in the fields of life sciences and information technology that have emerged since the 2000s. These innovations have transformed the landscape of healthcare, allowing for the simultaneous analysis of genes, cells, and proteins, and paving the way for a new era in diagnosis and treatment.

However, with these advancements have come new challenges, particularly the increasing complexity of diseases and the need for more precise and effective treatments.

Traditionally, disease diagnosis relied heavily on microscopy, but today, genetic analysis has revolutionized how we understand and classify illnesses. For instance, the case of Angelina Jolie, who underwent preventive surgery after discovering a genetic predisposition to breast cancer, highlights the potential of modern diagnostics.

Yet, this increased precision in diagnosis has also led to a paradox : the more specific the diagnosis, the fewer treatment options are available for some patients. This has created a critical need for new therapeutic solutions.

Recognizing this gap, we established our company to develop innovative therapies that address these unmet medical needs. Our mission is to create new treatments based on cutting-edge approaches such as gene therapy, cell therapy, and targeted protein therapeutics. The current state of drug discovery is limited in its ability to target only about 20% of the body’s potential druggable targets, leaving the remaining 80% classified as “undruggable.”

Despite these challenges, we believe that with persistent scientific innovation, it is possible to develop effective treatments even for these previously inaccessible targets.

Moreover, the complexity of diseases like cancer, where single-target therapies often fall short due to the emergence of drug resistance, has driven us to focus on the development of multi-functional therapeutics.

These new treatments, such as bispecific and trispecific antibodies, are designed to target multiple disease mechanisms simultaneously, offering hope for more effective and durable responses.

By pursuing these innovative approaches, our company aims to bring new hope to patients who currently have limited treatment options.

We are committed to advancing healthcare by developing therapies that not only improve patient outcomes but also enhance accessibility and reduce costs.

In doing so, we contribute to the broader goal of reducing the overall burden on healthcare systems worldwide.

In essence, our company was founded on the belief that through innovation and dedication, we can overcome the challenges posed by the complexity of modern diseases and make a meaningful impact on global health.

Vision & management philosophy

The core of our management philosophy is the unwavering belief in the power of innovation to overcome the most daunting challenges in healthcare. Our vision is to pioneer the future of medicine by "drugging the undruggables," targeting the 80% of disease mechanisms that have long been considered beyond the reach of current therapeutic approaches. We founded this company to address the critical gaps in treatment options, driven by a commitment to transforming scientific breakthroughs into life-changing therapies.

We understand that the complexity of modern diseases requires not just incremental advances, but bold, paradigm-shifting solutions. Our approach combines cutting-edge technologies in gene therapy, cell therapy, and multi-functional therapeutics to develop treatments that go beyond conventional methods.

Our management philosophy emphasizes three key principles
  • Innovation with Purpose

    We prioritize scientific discovery with a clear focus on addressing unmet medical needs. Every decision we make is guided by the potential to create therapies that offer hope where none previously existed.

  • Patient-Centric Leadership

    Our mission is deeply rooted in improving the lives of patients. We are committed to understanding and addressing the complexities of their conditions, ensuring that our innovations translate into meaningful clinical outcomes.

  • Collaborative Excellence

    We believe that groundbreaking advancements are achieved through collaboration. We foster an environment where diverse perspectives and expertise come together to push the boundaries of what is possible in drug development.

As we pursue our vision of drugging the undruggables, we remain steadfast in our dedication to advancing healthcare and making a lasting impact on the lives of patients worldwide.

Our management philosophy is not just about guiding our company's growth; it is about leading a movement toward a future where no disease is beyond reach.